ECSP23045508A - Inmunoterapia oncolítica por remodelación del microambiente tumoral - Google Patents
Inmunoterapia oncolítica por remodelación del microambiente tumoralInfo
- Publication number
- ECSP23045508A ECSP23045508A ECSENADI202345508A ECDI202345508A ECSP23045508A EC SP23045508 A ECSP23045508 A EC SP23045508A EC SENADI202345508 A ECSENADI202345508 A EC SENADI202345508A EC DI202345508 A ECDI202345508 A EC DI202345508A EC SP23045508 A ECSP23045508 A EC SP23045508A
- Authority
- EC
- Ecuador
- Prior art keywords
- remodeling
- oncolytic viruses
- oncolytic
- immunotherapy
- modified
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 230000000174 oncolytic effect Effects 0.000 title abstract 2
- 238000007634 remodeling Methods 0.000 title abstract 2
- 230000001173 tumoral effect Effects 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000012385 systemic delivery Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La divulgación se relaciona con virus oncolíticos modificados. Los virus oncolíticos modificados de la divulgación comprenden la modificación en el genoma viral que codifica ácidos nucleicos exógenos para potenciar la inmunoterapia oncolítica por la remodelación del microambiente tumoral y con un suministro sistémico potenciado. La divulgación se relaciona además con composiciones que comprenden los virus oncolíticos modificados, kits que los contienen, y métodos para el uso de los virus oncolíticos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063116004P | 2020-11-19 | 2020-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP23045508A true ECSP23045508A (es) | 2023-07-31 |
Family
ID=81709792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202345508A ECSP23045508A (es) | 2020-11-19 | 2023-06-19 | Inmunoterapia oncolítica por remodelación del microambiente tumoral |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230256041A1 (es) |
EP (1) | EP4247410A1 (es) |
JP (1) | JP2023552289A (es) |
KR (1) | KR20230110545A (es) |
CN (1) | CN116801899A (es) |
AU (1) | AU2021385059A1 (es) |
CA (1) | CA3197371A1 (es) |
CL (1) | CL2023001450A1 (es) |
CO (1) | CO2023006544A2 (es) |
CR (1) | CR20230268A (es) |
DO (1) | DOP2023000098A (es) |
EC (1) | ECSP23045508A (es) |
IL (1) | IL302897A (es) |
MX (1) | MX2023005853A (es) |
PE (1) | PE20231175A1 (es) |
TW (1) | TW202227621A (es) |
WO (1) | WO2022109133A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL71275A0 (en) * | 1983-03-21 | 1984-06-29 | Sparamedica Ag | Human interleukin-2-and its preparation |
DK2062023T4 (en) * | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
US11185586B2 (en) * | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
EP3703723A4 (en) * | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
KR20200116086A (ko) * | 2018-01-26 | 2020-10-08 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 종양 치료를 개선하기 위한 종양 미세환경에서 대사 조절인자의 발현 |
-
2021
- 2021-11-18 CN CN202180091007.7A patent/CN116801899A/zh active Pending
- 2021-11-18 TW TW110143069A patent/TW202227621A/zh unknown
- 2021-11-18 KR KR1020237019985A patent/KR20230110545A/ko unknown
- 2021-11-18 AU AU2021385059A patent/AU2021385059A1/en active Pending
- 2021-11-18 MX MX2023005853A patent/MX2023005853A/es unknown
- 2021-11-18 IL IL302897A patent/IL302897A/en unknown
- 2021-11-18 PE PE2023001681A patent/PE20231175A1/es unknown
- 2021-11-18 WO PCT/US2021/059887 patent/WO2022109133A1/en active Application Filing
- 2021-11-18 CA CA3197371A patent/CA3197371A1/en active Pending
- 2021-11-18 CR CR20230268A patent/CR20230268A/es unknown
- 2021-11-18 JP JP2023529962A patent/JP2023552289A/ja active Pending
- 2021-11-18 EP EP21895584.7A patent/EP4247410A1/en active Pending
-
2023
- 2023-02-03 US US18/105,374 patent/US20230256041A1/en active Pending
- 2023-05-17 DO DO2023000098A patent/DOP2023000098A/es unknown
- 2023-05-17 CO CONC2023/0006544A patent/CO2023006544A2/es unknown
- 2023-05-19 CL CL2023001450A patent/CL2023001450A1/es unknown
- 2023-06-19 EC ECSENADI202345508A patent/ECSP23045508A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023552289A (ja) | 2023-12-15 |
US20230256041A1 (en) | 2023-08-17 |
MX2023005853A (es) | 2023-06-02 |
TW202227621A (zh) | 2022-07-16 |
CO2023006544A2 (es) | 2023-05-19 |
EP4247410A1 (en) | 2023-09-27 |
IL302897A (en) | 2023-07-01 |
CL2023001450A1 (es) | 2023-10-20 |
KR20230110545A (ko) | 2023-07-24 |
DOP2023000098A (es) | 2023-08-15 |
PE20231175A1 (es) | 2023-08-01 |
CA3197371A1 (en) | 2022-05-27 |
CR20230268A (es) | 2023-07-26 |
WO2022109133A1 (en) | 2022-05-27 |
AU2021385059A1 (en) | 2023-06-08 |
CN116801899A (zh) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002912A1 (es) | Métodos para detectar aav. (divisional solicitud 201900392). | |
MX2019000252A (es) | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. | |
CL2017002731A1 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
BR112019010565A2 (pt) | aplicação viral de neoantígenos | |
CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
CO2017007105A2 (es) | Nuevos virus de tilapia | |
AR110632A1 (es) | Vectores del adenovirus canino | |
CL2018000164A1 (es) | Vector recombinante del virus orf. | |
UY39131A (es) | Composiciones y métodos para la inducción de una respuesta inmune | |
CL2021002807A1 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
CO2021013417A2 (es) | Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncer | |
BR112022001912A2 (pt) | Composições celulares compreendendo vetores virais e métodos de tratamento | |
CO2019012289A2 (es) | Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar | |
ECSP23045508A (es) | Inmunoterapia oncolítica por remodelación del microambiente tumoral | |
CO2021009271A2 (es) | Rhabdovirus recombinante que codifica ccl21 | |
CL2018002042A1 (es) | Metodos para la produccion de virus. | |
CO2018007442A2 (es) | Vacunas contra el cáncer | |
CL2023003199A1 (es) | Virus oncolíticos para la expresión modificada del mhc | |
AR117808A1 (es) | Virus de vacuna recombinante y métodos de uso del mismo | |
CL2019003108A1 (es) | Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar. | |
AR119105A1 (es) | Célula mutante bloqueada mdbk irf3 / irf7 y su uso para producción de vacunas | |
AR122385A1 (es) | VACUNA BASADA EN POXVIRUS RECOMBINANTES CONTRA EL VIRUS SARS-CoV-2 | |
AR114410A1 (es) | Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos | |
CL2022001176A1 (es) | Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida |